Kenneth Mulvany

Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.

Minster Pharmaceuticals Plc develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions. The company operates in Tonabersat and Sabcomeline segments. The Tonabersat segment is for the prevention and treatment of migraine. The Sabcomeline segment is for the management of cognitive decline and negative symptoms in schizophrenia. Minster Pharmaceuticals was founded by Robert Stubbs and Paul Sharpe in 2001 and is headquartered in London, the United Kingdom.

Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million.

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.